Hikal — 360° view

Hikal, a company in the Pharmaceuticals industry, reported revenue of ₹434 crore and a net loss of ₹6.10 crore for the September 2026 quarter.

Hikal (NSE: HIKAL) closed at ₹220.76 on 20 Nov 2026, down 3.3% over the past year. Its market capitalisation is ₹2,722 crore and it trades at 38.2 times earnings.

Share price
₹220.76 (20 Nov 2026)
Market cap
₹2,722 Cr (20 Nov 2026)
P/E
38.23 (20 Nov 2026)
Revenue
₹434 Cr (September 2026 quarter)
Net profit
₹-6 Cr (September 2026 quarter)
ROCE
3.50% (FY26)
ROE
2.21% (FY26)
Book value
₹95.8 (FY26)
Dividend yield
0.27% (last 12 months to 20 Nov 2026)
52-week high / low
₹261.00 / ₹146.25 (20 Nov 2026)
1-year return
-3.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: HIKAL

Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.